First detection of *Aspergillus fumigatus* azole-resistant strain due to Cyp51A TR46/Y121F/T289A in an azole-naive patient in Spain

T. Pelaez¹, M. C. Monteiro¹, R. Garcia-Rubio¹, E. Bouza¹, A. Gomez-Lopez² and E. Mellado²

¹) Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón and Department of Medicine, Faculty of Medicine, Universidad Complutense and ²) Mycology Reference Laboratory, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain

Abstract

We report the first isolation of a voriconazole-resistant *Aspergillus fumigatus* strain harbouring the azole resistance mechanism TR46/Y121F/T289A, recovered from an azole-naive patient in Spain with chronic obstructive pulmonary disease. This new finding in Spain suggests the spread of this resistance mechanism and reinforces the need for antifungal susceptibility surveillance.

New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.

Keywords: *Aspergillus fumigatus*, azole resistance spread, cyp51A, resistance mechanism

Original Submission: 6 November 2014; Accepted: 9 April 2015

Available online 20 April 2015

A 76-year-old man with increased basal dyspnoea, pleuritic-type chest pain and fever was admitted to the Hospital Gregorio Marañón, Madrid, in May 2014. The patient had been diagnosed with chronic obstructive pulmonary disease in 1997, and since then his baseline situation had worsened; he now manifested chronic respiratory failure treated with high-dose corticotherapy. In the present admission, *Aspergillus fumigatus* was cultured from sputum; however, galactomannan detection, calcofluor stain and PCR assay in bronchoalveolar lavage fluid were negative. The patient had no obvious clinical signs of invasive aspergillosis, and this isolation was considered a colonization following the revised EORTC/MSG criteria [1].

Strain identification (TP90812) was confirmed as *A. fumigatus* by PCR amplification and sequencing. The full coding sequences of the gene encoding the azole target (cyp51A gene including its promoter) was PCR amplified and sequenced [2], showing the newly described azole resistance mechanism, consisting of a 46 bp tandem repeat in the promoter region of cyp51A along with two punctual mutations in the coding sequence of the cyp51A gene (a433t and a936g), leading to substitutions of tyrosine to phenylalanine at codon 121 and a threonine to alanine at codon 289 (TR46/Y121F/T289A) [3].

Antifungal susceptibility test was performed using the broth microdilution method described by the European Committee on Antimicrobial Susceptibility Testing [4]. The *A. fumigatus* strain azole minimum inhibitory concentrations were itraconazole 2.0, voriconazole (VRC) >8.0 and posaconazole 0.5 and would be considered resistant to VRC and with intermediate minimum inhibitory concentration values to itraconazole and posaconazole [5].

The number of clinical isolates of azole-resistant *A. fumigatus* is gradually increasing. Triazole resistance can evolve during therapy, but resistant isolates are also being detected in azole-naive patients [6]. We report the first isolation of a VRC-resistant *A. fumigatus* strain TR46/Y121F/T289A in an azole-naive patient in Spain.

To date, *A. fumigatus* azole resistance is mostly associated to modifications of the target site (encoded by cyp51A) and its overexpression. The main azole resistance mechanism is mediated by a tandem repeat of 34 bases in the promoter of
cyp51A gene and a substitution in position 98 (TR34/L98H) [3]. This mechanism is spreading across Europe, and it has been related toazole fungicide use in agriculture [6]. A new resistance mechanism responsible for VRC resistance, TR46/Y121F/T289A in the cyp51A gene, was first detected in 2009 in a Dutch patient [4] and has recently been reported in other countries [7–10] (Table 1).

To our knowledge, this is the first case report of this specific mutation in an A. fumigatus clinical isolate in Spain. Although there has yet been not recovery of a TR46/Y121F/T289A azole-resistant A. fumigatus strains from the environment in Spain, its isolation from an azole-naive patient is an interesting finding, suggesting that an effective analysis of clinical and environmental sources must be done to detect azole resistance in A. fumigatus. The emergence and spread of this new azole resistance mechanism in A. fumigatus is of major concern because it conferred high resistance to VRC and is associated with treatment failure in patients with invasive aspergillosis [6,7].

**Conflict of interest**

None declared.

**Acknowledgements**

EM is supported by a Project from the Spanish Fondo de Investigación Sanitaria (FIS) (PI12_02376). MCM is funded by FIS by a Sara Borrell Fellowship (CD13/00198). TP is supported by a FIS project (PI14_02376).

---

**TABLE 1. Reports of azole-resistant strains carrying TR46/Y121F/T289A mutation in cyp51A gene, by country**

| Continent | First reported | No. of strains | Year | Origin | Study |
|-----------|----------------|----------------|------|--------|-------|
| Europe    |                |                |      |        |       |
| Germany   | 21             | 2009–11        | Clinical | [9] |
| The Netherlands | 1  | 2012            | Clinical | [3] |
| Belgium   | 1              | 2012           | Clinical | [7] |
| Denmark   | 1              | 2014           | Clinical | [9] |
| Spain     | 1              | 2014           | Clinical | This work |
| Africa    |                |                |      |        |       |
| Tanzania  | 4              | 2014           | Environment | [10] |
| Asia      |                |                |      |        |       |
| India     | 6              | 2012–13        | Environment | [10] |

---

**References**

[1] De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al., European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008 Jun 15;46(12):1813–21.

[2] Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Melchers WJ, Verweij PE, Cuenca-Estrella M, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007 Jun;51(6):1897–904.

[3] van der Linden JW, Camps SM, Kampinga GA, Arends JP, Debets-Ossenkopp YJ, Haas PJ, et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis 2013;57:513–20.

[4] Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW, European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole. Clin Microbiol Infect 2012;18:6248–50.

[5] Verweij PE, Howard SJ, Melchers WJ, Denning DW. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat 2009;12:141–7.

[6] van der Linden JW, Sneiders E, Kampinga GA, Rijnders BJ, Mattsson E, Debets-Ossenkopp YJ, et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007–2009. Emerg Infect Dis 2011;17:1846–54.

[7] Vermeulen E, Maertens J, Schoemans H, Lagrou K. Azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation emerging in Belgium, July 2012. Euro Surveill 2012;17(48).

[8] Fischer J, van Koningsbruggen-Rietschel S, Rietschel E, Vehreschild MJ, Wisplinghoff H, Krönke M, et al. Prevalence and molecular characterization of azole resistance in Aspergillus spp. isolates from German cystic fibrosis patients. J Antimicrob Chemother 2014 Jun;69(6):1533–6.

[9] Astrud KM, Jensen RH, Hassan TM, Mathiasen EG, Thomsen GM, Pedersen UG, et al. First detection of TR46/Y121F/T289A and of TR34/L98H inazole naive patients in Denmark despite negative findings in the environment. Antimicrob Agents Chemother 2014;58:5096–101.

[10] Chowdhary A, Sharma C, Hagen F, Meis JF. Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms. Future Microbiol 2014;9:697–711.